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current skin deterioration in patients suffering from 
moderate or severe psoriasis vulgaris underline the neces-
sity for innovative, long-lasting therapies with few 
side-effects.
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Quality of life questionnaires enable patients to express
their personal evaluation of the consequences of their
condition and/or treatment. Psoriasis has a heavy impact
on the physical and mental well-being of the patient.
OBJECTIVE: To evaluate the impact of the duration of
psoriasis on the quality of life of patients. METHOD:
Within the context of the SPOT study, 668 patients
(newly diagnosed patients: n = 319, Patients followed for
longer than 5 years: n = 347) responded to a quality of
life questionnaire consisting of a generic scale (SF-12) and
a speciﬁc scale (PDI–Psoriasis Disability Index). The com-
pleted questionnaires were returned in prepaid envelopes.
RESULTS: The socio-demographic proﬁle of the patients
in the two groups did not present any statistically signif-
icant difference (place of residence, lifestyle). The mean
age was respectively 42.9 years for newly diagnosed
patients versus 48.1 years for patients who had been fol-
lowed for longer than 5 years. The PDI score was 10.7%
(SD = 11.7) for newly diagnosed patients and 15.7% (SD
= 13.5) for patients that had been followed for longer
than 5 years (p < 0.0001). With regard to the SF-12, the
results were organised in 2 scores: mental (MCS-12) and
physical (PCS-12). The scores for newly diagnosed
patients were: PCS-12 = 52.4 (SD = 7.1) & MCS-12 =
42.8 (SD = 10.5) the scores for the Patients followed for
longer than 5 years were: PCS-12 = 50.6 (SD = 8.0) &
MCS-12 = 41.0 (SD = 10.7). The differences observed in
the two dimensions, physical and mental, were statisti-
cally signiﬁcant (p = 0.0038 and p = 0.0281). CON-
CLUSION: These results show a quality of life’s
impairing for the population that had been followed for
longer than 5 years, a difference conﬁrmed by both the
speciﬁc and generic scales.
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Psoriasis is a chronicle disease, which concerns 4.7% of
the European population. Even if it does not question the
vital prognosis, it is a very invalidating condition in daily
life because of the damage to the body image. Therefore
the patients’ quality of life improvement is one of the
medical treatment’s priority. OBJECTIVE: To assess the
impact of a medical strategy on patients’ quality of life.
METHOD: SPOT is a longitudinal, prospective observa-
tional program following 400 psoriasis patients in Spain
The Psoriasis Disability Index (Pr Finlay, 1987) and the
SF12 are evaluated, the completed questionnaires were
returned by post. RESULTS: In this ﬁrst analysis, the ﬁrst
74 patients were taken into account and analysed at inclu-
sion and 3 months after the treatment initiation. The PDI
score at inclusion is 11.88 (sd = 10). The PDI score 3
months after is 8.88 (sd = 9.48). These ﬁrst results show
evidence of an improvement of patients’ quality of life 3
months after treatments (p < 0.02). Concerning the SF-
12, the results consisted of two scores: mental (MCS-12)
and physical (PCS-12). At inclusion the SF12 scores were:
PCS-12 = 50 (sd = 8) & MCS-12 = 49.9 (sd = 9.8), 3
months after the scores were the following PCS-12 = 52
(sd = 7.6) & MCS-12 = 50.7 (sd:7.6). The improvement
of the quality of life in their physical health dimension is
statistically signiﬁcant (p < 0.03). CONCLUSION: Con-
cerning the PDI, the following dimensions “daily activi-
ties, leisure and social relations” are signiﬁcantly
improved (p < 0.02), which might have consequences on
patients’ daily life.
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Skin diseases have a strong impact on the physical and
mental well-being of the patient. The large number of
quality of life studies that exist conﬁrms this. OBJEC-
TIVES: To evaluate the effect of psoriasis on quality of
life of patients in Spain. METHOD: A total of 4500
anonymous questionnaires (comprised of two scales: the
Psoriasis Disability Index (PDI) plus 10 questions con-
cerning treatment and evolution of psoriasis) were sent,
via a Psoriasis Patient Support Group (AccionPsoriasis).
RESULTS: A total of 1900 questionnaires were returned
(June 2002): response rate 42%. An analysis of the ﬁrst
810 questionnaires was realised. The sex ratio Men
(M)/Women(W) was: 49/51. Mean age: 42 years. Mean
age of diagnosis: 21.8 years. The average to the total score
was 8.47 (s.d. 7.2 rank 0 to 39) i.e. 18.82 (s.d.: 17.2)
when reported to a scale of 0 to 100. Signiﬁcant differ-
ence was observed between M and W for the global 
handicap score 20.73 vs 16.95 p < 0.002. Two groups
was identiﬁed: pousée de psoriasis (84%), pas de poussée
de psorisis (12%)—no answers (4%). Psoriasis had a
greater adverse affect on patients with crise: PDI score =
20.24 (sd 17.52) than the patient without actual crise 
PDI score = 8.98 (sd 11.34). This difference was signi-
ﬁcative p < 0.00001. CONCLUSION: These results high-
light the value of appropriate and relevant psychological
